Back

Effect of intravenous ferric carboxymaltose on oxidative stress markers in patients with heart failure and iron deficiency

10 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Iron deficiency and anaemia in heart failure Comorbidities HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ertugrul Yencilek

Ankara Etlik City Hospital, Ankara (Turkiye)

6 More presentations in this session

Presentation thumbnail
Low transferrin saturation predicts mortality in HFrEF across anemia strata: a registry-based IPTW analysis
Mr H. Nahoui (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Sex differences in response to ferric carboxymaltose in heart failure: molecular insights from AFFIRM-AHF
Mr R. Alnuwaysir (Groningen, NL) Doctor N. Grote Beverborg (Groningen, NL)
Abstract Slides
Presentation thumbnail
Short-term changes in left ventricular systolic function in patients with heart failure after iron repletion: the role of dyssynchrony
Miss I. Del Canto Serrano (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Proton-pump inhibitor use as a modifiable etiological factor for iron deficiency in heart failure
Mr M. Kutscher (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Association of mean corpuscular volume patterns with heart failure prevalence in US adults
Mr Y. Raza (Norwich, GB)
Abstract Slides

Access the full session

Session thumbnail
Iron deficiency and anaemia in heart failure

The Event

Event poster

Heart Failure 2026

10 May 2026 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Ferric carboxymaltose modulates metabolic and inflammatory pathways alongside erythropoiesis in heart failure: mechanistic insights from the AFFIRM-AHF
thumbnail
Congress Presentation
Treatment of iron deficiency in heart failure in 2023
thumbnail
Congress Presentation
Iron therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources